Manhattan Drug, a wholly owned unit of Integrated BioPharma, named Michael G. Richtmyer head of operations, effective Aug. 3, 2026.
Richtmyer will run manufacturing performance, supply chain reliability, quality systems, productivity, scalable growth across the contract supplement manufacturer.
He most recently led Tishcon as president, overseeing two contract manufacturing sites with responsibility for operations, quality, sales, budgets.
INBP•
